Completed

ACTMMACT PET/CT and F18-FDG PET/CT Comparison in Multiple Myeloma Staging and Response Assessment

0 criteria met from your profileSee at a glance how your profile meets each eligibility criteria.
Study Aim

This study compares the accuracy of ACT PET/CT and F18-FDG PET/CT scans in detecting lesions before treatment in individuals with multiple myeloma, using bone marrow examination and whole-body dynamic contrast-enhanced MRI as reference standards.

What is being tested

Advanced ACT PET/CT Scan

Other
Who is being recruted

Blood Protein Disorders+12

+ Cardiovascular Diseases

+ Hematologic Diseases

Over 20 Years
+8 Eligibility Criteria
See all eligibility criteria
How is the trial designed

Diagnostic Study

Interventional
Study Start: May 2011
See protocol details

Summary

Principal SponsorChang Gung Memorial Hospital
Last updated: November 13, 2015
Sourced from a government-validated database.Claim as a partner

Study start date: May 1, 2011

Actual date on which the first participant was enrolled.

Multiple myeloma is a type of cancer that affects a certain type of white blood cells. This study is exploring the use of a specific imaging technique called C11-Acetate PET/CT in multiple myeloma patients. The goal is to see if this technique can help detect cancer lesions before treatment and evaluate how well the treatment is working, compared to a more commonly used method called F18-Fluorodeoxyglucose PET/CT. This research could potentially improve the way doctors stage and assess multiple myeloma, leading to better patient care. During the study, participants will undergo the C11-Acetate PET/CT scan. The results will then be compared with the results from a bone marrow examination and a whole-body dynamic contrast-enhanced MRI, which are currently used as standard methods. The study will assess how well the C11-Acetate PET/CT scan can detect lesions before treatment, providing valuable insights into its potential clinical utility.

NCT01691300
Principal SponsorChang Gung Memorial Hospital
Last updated: November 13, 2015
Sourced from a government-validated database.Claim as a partner

Protocol

This section provides details of the study plan, including how the study is designed and what the study is measuring.
Design Details

30 patients to be enrolled

Total number of participants that the clinical trial aims to recruit.

Diagnostic Study

Diagnostic studies focus on improving how we detect or confirm a disease. They test new tools or techniques that could provide faster or more accurate diagnoses.

Eligibility

Researchers look for people who fit a certain description, called eligibility criteria: person's general health condition or prior treatments.
Conditions
Criteria

Any sex

Biological sex of participants that are eligible to enroll.

Over 20 Years

Range of ages for which participants are eligible to join.

Healthy volunteers not allowed

If individuals who are healthy and do not have the condition being studied can participate.

Conditions

Pathology

Blood Protein DisordersCardiovascular DiseasesHematologic DiseasesHemic and Lymphatic DiseasesHemorrhagic DisordersImmune System DiseasesImmunoproliferative DisordersLymphoproliferative DisordersNeoplasmsNeoplasms by Histologic TypeParaproteinemiasVascular DiseasesHemostatic DisordersNeoplasms, Plasma CellMultiple Myeloma

Criteria

4 inclusion criteria required to participate
at least 20 years of age
complete pre-treatment clinical staging including bone marrow examination
previously untreated
written informed consent to participate in the study
4 exclusion criteria prevent from participating
concurrent active malignant tumor(s)
marked renal impairment (contraindicated for contrast-enhanced MRI)
non-compliant to PET/CT or to MRI
pregnant or breast feeding women

Study Plan

Find out more about all the medication administered in this study, their detailed description and what they involve.
Treatment Groups
Study Objectives

One single intervention group is designated in this study

This study does not include a placebo group 

Treatment Groups

Group I

Experimental
Dual-tracer ACT/FDG PET/CT and WB-DCE-MRI at baseline (pretreatment), post-induction and post-ASCT (if eligible)

Study Objectives

Primary Objectives

Secondary Objectives

Study Centers

These are the hospitals, clinics, or research facilities where the trial is being conducted. You can find the location closest to you and its status.

This study has 1 location

Chang Gung Memorial Hostpial

Guishan, TaiwanOpen Chang Gung Memorial Hostpial in Google Maps
CompletedOne Study Center